A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism
Trial · NCT02910466
Results by group354
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 354
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline (402) in Concentration of Albumin-corrected Serum Calcium (ACSC) at Month 6 | rhPTH(1-84) | -0.005 | Standard Deviation 0.1546 | Millimole per liter (mmol/L) | |
| Change From Baseline (402) in Concentration of Albumin-corrected Serum Calcium (ACSC) at Month 12 | rhPTH(1-84) | 0.069 | Standard Deviation 0.1838 | mmol/L | |
| Change From Baseline (402) in Concentration of Albumin-corrected Serum Calcium (ACSC) at Month 18 | rhPTH(1-84) | 0.066 | Standard Deviation 0.2158 | mmol/L | |
| Change From Baseline (402) in Concentration of Albumin-corrected Serum Calcium (ACSC) at Month 24 | rhPTH(1-84) | 0.112 | Standard Deviation 0.2314 | mmol/L | |
| Change From Baseline (402) in Concentration of Albumin-corrected Serum Calcium (ACSC) at Month 30 | rhPTH(1-84) | 0.145 | Standard Deviation 0.2447 | mmol/L | |
| Change From Baseline (402) in Concentration of Albumin-corrected Serum Calcium (ACSC) at Month 36 | rhPTH(1-84) | 0.170 | Standard Deviation NA | mmol/L | |
| Change From Baseline (402) in Concentration of Albumin-corrected Serum Calcium (ACSC) at End of Treatment (EOT) (up to Month 36) | rhPTH(1-84) | 0.135 | Standard Deviation 0.2260 | mmol/L | |
Percentage of Participants Who Achieved ACSC Concentrations Above, Below, or in the Range of 1.875 mmol/L (7.5 Milligram Per Deciliter [mg/dL]) to Upper Limit of Normal (ULN) at Month 6, 12, 18, 24, 30, 36 and EOT (up to Month 36) | rhPTH(1-84) | At Month 6: less than (<) 1.875 mmol/L | 20.8 | Percentage of participants | |
Percentage of Participants Who Achieved ACSC Concentrations Above, Below, or in the Range of 1.875 mmol/L (7.5 Milligram Per Deciliter [mg/dL]) to Upper Limit of Normal (ULN) at Month 6, 12, 18, 24, 30, 36 and EOT (up to Month 36) | rhPTH(1-84) | At Month 6: 1.875 mmol/L to ULN | 79.2 | Percentage of participants | |
Percentage of Participants Who Achieved ACSC Concentrations Above, Below, or in the Range of 1.875 mmol/L (7.5 Milligram Per Deciliter [mg/dL]) to Upper Limit of Normal (ULN) at Month 6, 12, 18, 24, 30, 36 and EOT (up to Month 36) | rhPTH(1-84) | At Month 6: >ULN | 0 | Percentage of participants | |
Percentage of Participants Who Achieved ACSC Concentrations Above, Below, or in the Range of 1.875 mmol/L (7.5 Milligram Per Deciliter [mg/dL]) to Upper Limit of Normal (ULN) at Month 6, 12, 18, 24, 30, 36 and EOT (up to Month 36) | rhPTH(1-84) | At Month 12: <1.875 mmol/L | 31.3 | Percentage of participants | |
Percentage of Participants Who Achieved ACSC Concentrations Above, Below, or in the Range of 1.875 mmol/L (7.5 Milligram Per Deciliter [mg/dL]) to Upper Limit of Normal (ULN) at Month 6, 12, 18, 24, 30, 36 and EOT (up to Month 36) | rhPTH(1-84) | At Month 12: 1.875 mmol/L to ULN | 65.6 | Percentage of participants | |
Percentage of Participants Who Achieved ACSC Concentrations Above, Below, or in the Range of 1.875 mmol/L (7.5 Milligram Per Deciliter [mg/dL]) to Upper Limit of Normal (ULN) at Month 6, 12, 18, 24, 30, 36 and EOT (up to Month 36) | rhPTH(1-84) | At Month 12: > ULN | 3.1 | Percentage of participants | |
Percentage of Participants Who Achieved ACSC Concentrations Above, Below, or in the Range of 1.875 mmol/L (7.5 Milligram Per Deciliter [mg/dL]) to Upper Limit of Normal (ULN) at Month 6, 12, 18, 24, 30, 36 and EOT (up to Month 36) | rhPTH(1-84) | At Month 18: <1.875 mmol/L | 24.2 | Percentage of participants | |
Percentage of Participants Who Achieved ACSC Concentrations Above, Below, or in the Range of 1.875 mmol/L (7.5 Milligram Per Deciliter [mg/dL]) to Upper Limit of Normal (ULN) at Month 6, 12, 18, 24, 30, 36 and EOT (up to Month 36) | rhPTH(1-84) | At Month 18: 1.875 mmol/L to ULN | 75.8 | Percentage of participants | |
Percentage of Participants Who Achieved ACSC Concentrations Above, Below, or in the Range of 1.875 mmol/L (7.5 Milligram Per Deciliter [mg/dL]) to Upper Limit of Normal (ULN) at Month 6, 12, 18, 24, 30, 36 and EOT (up to Month 36) | rhPTH(1-84) | At Month 18: >ULN | 0 | Percentage of participants | |
Percentage of Participants Who Achieved ACSC Concentrations Above, Below, or in the Range of 1.875 mmol/L (7.5 Milligram Per Deciliter [mg/dL]) to Upper Limit of Normal (ULN) at Month 6, 12, 18, 24, 30, 36 and EOT (up to Month 36) | rhPTH(1-84) | At Month 24: <1.875 mmol/L | 16.7 | Percentage of participants | |
Percentage of Participants Who Achieved ACSC Concentrations Above, Below, or in the Range of 1.875 mmol/L (7.5 Milligram Per Deciliter [mg/dL]) to Upper Limit of Normal (ULN) at Month 6, 12, 18, 24, 30, 36 and EOT (up to Month 36) | rhPTH(1-84) | At Month 24: 1.875 mmol/L to ULN | 83.3 | Percentage of participants | |
Percentage of Participants Who Achieved ACSC Concentrations Above, Below, or in the Range of 1.875 mmol/L (7.5 Milligram Per Deciliter [mg/dL]) to Upper Limit of Normal (ULN) at Month 6, 12, 18, 24, 30, 36 and EOT (up to Month 36) | rhPTH(1-84) | At Month 24: >ULN | 0 | Percentage of participants | |
Percentage of Participants Who Achieved ACSC Concentrations Above, Below, or in the Range of 1.875 mmol/L (7.5 Milligram Per Deciliter [mg/dL]) to Upper Limit of Normal (ULN) at Month 6, 12, 18, 24, 30, 36 and EOT (up to Month 36) | rhPTH(1-84) | At Month 30: <1.875 mmol/L | 17.4 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02910466/results